Improving Anaphylaxis Outcomes: Approaches for Enhancing Access to Epinephrine; Public Workshop; Request for Comments

Resumen

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled "Improving Anaphylaxis Outcomes: Approaches for Enhancing Access to Epinephrine." The purpose of the public workshop is to initiate a discussion on expanding epinephrine accessibility and use, including in community settings, to reduce anaphylaxis-related morbidity and mortality. This public workshop will be convened and supported by a cooperative agreement between FDA and the Duke-Margolis Institute for Health Policy.